Systematic review: symptoms of rebound acid hypersecretion following proton pump inhibitor treatment

References

• U.S. Food and Drug Administration. Rebound of gastric acid secretion. 2000. Available from http://www.fda.gov/ohrms/dockets/ac/00/backgrd/3650b1a_11.pdf.
   Google Scholar
• Waldum HL, Qvigstad G, Fossmark R, Kleveland PM, Sandvik AK. Rebound acid hypersecretion from a physiological, pathophysiological and clinical viewpoint. Scand J Gastroenterol 2010;45:389–94.
   PubMed Web of Science ®Google Scholar
• Waldum HL, Arnestad JS, Brenna E, Eide I, Syversen U, Sandvik a K. Marked increase in gastric acid secretory capacity after omeprazole treatment. Gut 1996;39:649–53.
   PubMed Web of Science ®Google Scholar
• Fossmark R, Johnsen G, Johanessen E, Waldum HL. Rebound acid hypersecretion after long-term inhibition of gastric acid secretion. Aliment Pharmacol Ther 2005;21:149–54.
   PubMed Web of Science ®Google Scholar
• Gillen D, Wirz AA, Ardill JE, McColl KE. Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status. Gastroenterology 1999;116:239–47.
   PubMed Web of Science ®Google Scholar
• McColl KEL, Gillen D. Evidence that proton-pump inhibitor therapy induces the symptoms it is used to treat. Gastroenterology 2009;137:20–2.
   PubMed Web of Science ®Google Scholar
• Abrahamsen B, Eiken P, Eastell R. Proton pump inhibitor use and the antifracture efficacy of alendronate. Arch Intern Med 2011;171:998–1004.
   PubMed Web of Science ®Google Scholar
• Moayyedi P, Mason J. Clinical and economic consequences of dyspepsia in the community. Gut 2002;50:iv10–12.
   PubMed Web of Science ®Google Scholar
• Howell M, Novack V. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med 2010;170:784–90.
   PubMed Web of Science ®Google Scholar
• Hunfeld NGM, Geus WP, Kuipers EJ. Systematic review: Rebound acid hypersecretion after therapy with proton pump inhibitors. Aliment Pharmacol Ther 2007;25:39–46.
   PubMed Web of Science ®Google Scholar
• Nwokolo CU, Prewett EJ, Sawyerr AM, Hudson M, Lim S, Pounder RE. Tolerance during 5 months of dosing with ranitidine, 150 mg nightly: a placebo-controlled, double-blind study. Gastroenterology 1991;101:948–53.
   PubMed Web of Science ®Google Scholar
• Reimer C, Bytzer P. Discontinuation of long-term proton pump inhibitor therapy in primary care patients: a randomized placebo-controlled trial in patients with symptom relapse. Eur J Gastroenterol Hepatol 2010;22:1182–8.
   PubMed Web of Science ®Google Scholar
• Wada Y, Ito M, Takata S, Kitamura S, Takamura A, Tatsugami M, Little necessity of acid inhibition against proton pump inhibitor rebound effects and prior helicobacter pylori eradication therapy in gastric ulcer patients: a randomized prospective study. Hepato-Gastroenterol 2009;56:624–8.
   Google Scholar
• Reimer C, Søndergaard B, Hilsted L, Bytzer P. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology 2009;137:80–7; 87.
   PubMed Web of Science ®Google Scholar
• Niklasson A, Lindström L, Simrén M, Lindberg G, Björnsson E. Dyspeptic symptom development after discontinuation of a proton pump inhibitor: a double-blind placebo-controlled trial. Am J Gastroenterol 2010;105:1531–7.
   PubMed Web of Science ®Google Scholar
• Farup PG, Juul-Hansen PH, Rydning A. Does short-term treatment with proton pump inhibitors cause rebound aggravation of symptoms? J Clin Gastroenterol 2001;33:206–9.
   Google Scholar
• Juul-Hansen P, Rydning A. Clinical and pathophysiological consequences of on-demand treatment with PPI in endoscopy-negative reflux disease. Is rebound hypersecretion of acid a problem? Scand J Gastroenterol 2011;46:398–405.
   PubMed Web of Science ®Google Scholar
• Metz DC, Pilmer BL, Han C, Perez MC. Withdrawing PPI therapy after healing esophagitis does not worsen symptoms or cause persistent hypergastrinemia: analysis of dexlansoprazole MR clinical trial data. Am J Gastroenterol 2011;106:1953–60.
   PubMed Web of Science ®Google Scholar
• Sharma P, Shaheen NJ, Perez MC, Pilmer BL, Lee M, Atkinson SN, Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation–results from two randomized controlled studies. Aliment Pharmacol Ther 2009;29:731–41.
   PubMed Web of Science ®Google Scholar
• Metz DC, Howden CW, Perez MC, Larsen L, O'Neil J, Atkinson SN. Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis. Aliment Pharmacol Ther 2009;29:742–54.
   PubMed Web of Science ®Google Scholar
• Howden CW, Larsen LM, Perez MC, Palmer R, Atkinson SN. Clinical trial: efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis - maintenance of healing and symptom relief. Aliment Pharmacol Ther 2009;30:895–907.
   PubMed Web of Science ®Google Scholar
• Ryberg B, Tielemans Y, Axelson J, Carlsson E, Håkanson R, Mattson H, Gastrin stimulates the self-replication rate of enterochromaffinlike cells in the rat stomach. Effects of omeprazole, ranitidine, and gastrin-17 in intact and antrectomized rats. Gastroenterology 1990;99:935–42.
   PubMed Web of Science ®Google Scholar
• Lamberts R, Creutzfeldt W, Strüber HG, Brunner G, Solcia E. Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. Gastroenterology 1993;104:1356–70.
   PubMed Web of Science ®Google Scholar
• Gillen D, Wirz AA, McColl KEL. Helicobacter pylori eradication releases prolonged increased acid secretion following omeprazole treatment. Gastroenterology 2004;126:980–8.
   PubMed Web of Science ®Google Scholar
• Sharma BK, Walt RP, Pounder RE, Gomes MD, Wood EC, Logan LH. Optimal dose of oral omeprazole for maximal 24 hours decrease of intragastric acidity. Gut 1984;25:957–64.
   PubMed Web of Science ®Google Scholar
• Sharma B, Axelson M, Pounder RP, Lundborg P, Ohman M, Santana A, Acid secretory capacity and plasma gastrin concentration after administration of omeprazole to normal subjects. Aliment Pharmacol Ther 1987;1:67–76.
   PubMedGoogle Scholar
• Bell N, Karol MD, Sachs G, Greski-Rose P, Jennings DE, Hunt RH. Duration of effect of lansoprazole on gastric pH and acid secretion in normal male volunteers. Aliment Pharmacol Ther 2001;15:105–13.
   PubMed Web of Science ®Google Scholar
• El-Omar EM. Mechanisms of increased acid secretion after eradication of Helicobacter pylori infection. Gut 2006;55:144–6.
   Google Scholar
• Raghunath a S, O'Morain C, McLoughlin RC. Review article: the long-term use of proton-pump inhibitors. Aliment Pharmacol Ther 2005;22:55–63.
   Google Scholar
• Naunton M, Peterson GM, Bleasel MD. Overuse of proton pump inhibitors. J Clin Pharmacol Ther 2000;25:333–40.
   PubMed Web of Science ®Google Scholar
• Ronkainen J, Aro P, Storskrubb T, Johansson S-E, Lind T, Bolling-Sternevald E, High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population: A Kalixanda study report. Scand J Gastroenterol 2005;40:275–85.
   PubMed Web of Science ®Google Scholar
• Smith a D, Gillen D, Cochran KM, El-Omar E, McColl KE. Dyspepsia on withdrawal of ranitidine in previously asymptomatic volunteers. Am J Gastroenterol 1999;94:1209–13.
   Google Scholar
• Raines D, Chester M, Diebold AE, Mamikunian P, Anthony CT, Mamikunian G, A prospective evaluation of the effect of chronic proton pump inhibitor use on plasma biomarker levels in humans. Pancreas 2012;41:508–11.
   Web of Science ®Google Scholar
• Hyun JJ, Bak Y. Clinical Significance of Hiatal Hernia. Gut Liver 2011;5:267–77.
   PubMed Web of Science ®Google Scholar
• Hirschowitz BI. A critical analysis, with appropriate controls, of gastric acid and pepsin secretion in clinical esophagitis. Gastroenterology 1991;101:1149–58.
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Sonnenberg A, Jamal MM, Inadomi JM, Crooks LA, Feddersen RM. Corpus gastritis is protective against reflux oesophagitis. Gut 1999;45:181–5.
   PubMed Web of Science ®Google Scholar
• Björnsson E, Abrahamsson H, Simrén M, Mattsson N, Jensen C, Agerforz P, Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial. Aliment Pharmacol Ther 2006;24:945–54.
   PubMed Web of Science ®Google Scholar